CNBG-Virogin’s Omicron-Targeted mRNA Vaccine Approved for Clinical Trials
CNBG-Virogin Biotech (Shanghai) Co., Ltd has announced obtaining clinical trial approval from the National Medical...
Fineline Cube
Hepagene’s FXR Agonist HPG1860 Shows Positive Phase IIa Data in NASH Study
China-based liver disease specialist Hepagene Therapeutics (HK) Limited has revealed positive data from the Phase...
Ascentage Pharma Raises HKD 550 Million in Secondary Offering for Pipeline Expansion
Suzhou-based Ascentage Pharma (HKG: 6855) is set to conduct a secondary offering of 22.5 million...
BMS’s Opdivo Approved in China for Neoadjuvant Therapy in Urothelial Carcinoma
US-based Bristol-Myers Squibb (BMS, NYSE: BMY) has secured another new indication approval in China for...
NHSA Updates 2022 National Reimbursement Drug List with 2,967 Drug Varieties
The National Healthcare Security Administration (NHSA) has revealed the results of the 2022 National Reimbursement...
Harbour BioMed Receives FDA Approval for HBM1007 Clinical Study
China-based Harbour BioMed (HKG: 2142) has announced receiving approval from the US FDA to initiate...
Joincare’s Biosimilar Tocilizumab Approved for Marketing in China
China-based Joincare Pharmaceutical Industry Group Co., Ltd (SHA: 600380) has announced that its subsidiary Zhuhai...
CANbridge Pharmaceuticals Initiates Phase II Dosing for CAN103 in Gaucher Disease
China-based CANbridge Pharmaceuticals, Inc. (HKG: 1228) has announced the first patient dosing in the Phase...
GenScript ProBio Closes $220M Series C Financing for Biologics and Gene Therapy Expansion
Contract Development and Manufacturing Organization (CDMO) GenScript ProBio has announced the completion of a $220...
Roche and HKSTP Collaborate to Boost Life Sciences in Greater Bay Area
Swiss pharmaceutical giant Roche (SWX: ROG) has signed a multi-faceted collaboration agreement with the Hong...
Burning Rock Upgrades 2022 Revenue Growth Forecast to 10% YOY
Guangzhou-based medical device giant Burning Rock Ltd (NASDAQ: BNR) has issued a notice upgrading its...
Pasithea Therapeutics Partners with WuXi AppTec for API Manufacturing of PAS-004
US-based Pasithea Therapeutics Corp. (NASDAQ: KTTA) has announced that Chinese Contract Research Organization (CRO) WuXi...
NHSA Completes 2022 NRDL Update with 111 New Listings, Focus on COVID-19 Treatments
The National Healthcare Security Administration (NHSA) held a press conference to mark the completion of...
CDE Grants Priority Review to Takeda’s Vonicog Alfa, Zhongmei’s Rilonacept, and Zai Lab’s SUL-DUR
The Center for Drug Evaluation (CDE) has indicated that Takeda’s Vonicog alfa, Zhongmei Huadong Pharma’s...
Immunofoco’s CLDN18.2-Targeted CAR-T Therapy IMC002 Accepted for CDE Review
China’s Center for Drug Evaluation (CDE) has accepted a clinical trial filing for IMC002, an...
Keymed Biosciences’ CMG901 Shows Promising Results in Phase Ia Study for Solid Tumors
China-based Keymed Biosciences Inc. (HKG: 2162) has revealed the latest data update from a Phase...
MDHC Group Raises Hundreds of Millions in Third Financing Round
Jiangsu-based MDHC Life Technologies (Kunshan) Co.,Ltd, a leading platform in minimally invasive surgery and life...
Staidson’s STSP-0601 Begins Phase II Study for Hemophilia Treatment
China-based Staidson (Beijing) Pharmaceutical Co., Ltd (SHE: 300204) has announced the first subject dosing in...
Everest Medicines’ EVER206 Shows Positive Phase I Results in China
China-based Everest Medicines (HKG: 1952) has announced top-line results from a Phase I study in...
Bliss Bio Raises RMB 100 Million in Series B+ Financing for Oncology Pipeline
Hangzhou-based oncology-focused clinical-stage biotech Bliss Bio has reportedly raised over RMB 100 million (USD 14.7...